Introduction
The bone marrow microenvironment plays an important role in maintaining the quiescence and plasticity of hematopoietic stem cells (HSCs). The stem-cell properties are controlled by ligandreceptor signaling and cell-cell adhesion molecules within microenvironmental niches. These anatomical sites predominantly consist of spindle-shaped, N-cadherin -positive endosteal osteoblasts at the bone surface and VE-cadherin-positive sinusoidal endothelium at the thin-walled blood vessels (sinusoids). 1, 2 The molecular mechanisms underlying interactions between stem cells and their niche are better understood in the context of Drosophila germ stem cells and mouse bone marrow than in humans. In Drosophila ovary, the molecular hinge that anchors germ stem cells to cap cells (niche stromal cells) is E-cadherin and ␤-catenin. 3 In the mouse model of the HSC microenvironment, N-cadherin is expressed in both quiescent HSCs and osteoblasts, and an increase in the number of N-cadherin ϩ osteoblasts is correlated with an increase in N-cadherin ϩ HSCs. 1, 4 Although the effect of bone marrow niches on normal hematopoietic stem and progenitor cells has been extensively investigated, less is known about how the same microenvironment influences leukemic stem cells (LSCs). Although LSCs show a symbiotic relationship with the specialized bone marrow microenvironment, 5 the role of bone marrow fibroblastic stromal cells in supporting self-renewal of acute lymphoblastic leukemia (ALL) LSCs remains largely unclear. Recent studies indicated that the canonical Wnt/␤-catenin signaling pathway plays a pivotal role in B-lineage hematopoietic stem-and progenitor-cell development. 6 In addition to the destruction and transcription complexes involved in the Wnt signaling pathway, ␤-catenin also exists in the cadherin-catenin-actin cell-cell adhesion complex. 7 VE-cadherin (vascular-endothelial cadherin) is one of the classic Ca 2ϩ -dependent, homophilic adhesion molecules primarily expressed in endothelial cell adherens junctions. The intracellular domain of VE-cadherin physically interacts with p120 catenin, ␤-catenin, ␣-catenin, and the actin cytoskeleton. Tyrosine phosphorylation of the C-terminus of ␤-catenin at Tyr142, or the VE-cadherin intracellular domain at Tyr 658/731 by Src family kinases, alters the binding affinity of ␤-catenin to VE-cadherin. 8, 9 Interplay between ␤-catenin and cadherin family proteins may modulate the stem-cell properties of normal HSCs. Whether this interaction influences LSC maintenance and progression and how this interaction contributes to sustained leukemic cell self-renewal warrant further investigation. We present data showing that a putative LSC subset of ALL uses the Bcr-abl/VE-cadherin/␤-catenin axis to bypass the requirement of externally stimulated Wnt/␤-catenin. Although dependence on microenvironment cues for self-renewal is lost, the ability of leukemic cells to respond to stromal signals is maintained. Stromal cells regulate self-renewal and proliferation of this Philadelphia-chromosome positive (Ph ϩ )/ VE-cadherin ϩ LSC-like subpopulation by up-regulation of VEcadherin and Bcr-abl expression.
Materials and methods

Cells and reagents
Ph ϩ ALL cell line Sup-B15 (p185 Bcr-abl ϩ ) was obtained from ATCC (Manassas, VA). Nalm27 (p210 Bcr-abl ϩ ), Nalm20, and Nalm29 ALL cell lines were kindly provided by the Fujisaki Cancer Center, Okayama, Japan. Control cell lines JM1, RS4;11, REH, Jurkat, HL60, and K562 were also from ATCC. Ph ϩ OP-1 was a gift from Dr Dario Campana (St Jude Children's Research Hospital, Memphis, TN). Maintenance of human bone marrow-derived stromal cell line PatX and murine stromal cell line S-10 (provided by Dr Kenneth Dorshkind of the University of California) has been previously described in detail. 10 To establish long-term coculture of stromal and leukemic cells, Sup-B15 and Nalm27 cells were seeded onto 70% confluent stromal cells and maintained by subculture of a portion of Sup-B15 or Nalm27 cells onto new stromal cells weekly for more than 12 months. Bcr-abl kinase inhibitors Imatinib Mesylate (IM) and AG957 were obtained from Novartis (Basel, Switzerland) and Sigma (St Louis, MO), respectively. Src kinase inhibitor PP2 and proteosome inhibitor MG132 were purchased from Calbiochem (San Diego, CA). All recombinant cytokines and growth factors were purchased from R&D Systems (Minneapolis, MN).
Plasmid constructs, lentiviral vectors, and retroviral vectors
Human VE-cadherin (referred to as CDH5/wild type, wt), VE-cadherin lacking the C-terminal 222-nt ␤-catenin binding domain (referred to as ⌬bcat), and VE-cadherin lacking the C-terminal 449-nt cytoplasmic domain (referred to as ⌬cyto) coding DNA sequences (CDSs) were amplified with high-fidelity DNA polymerase pfx (Invitrogen, Carlsbad, CA) from a human umbilical cord vein endothelial cell cDNA library and subsequently ligated into the pENTR-D/TOPO entry vector using the TOPO cloning strategy (Invitrogen). The 2 truncated derivates and the wt VE-cadherin pENTR entry plasmid constructs were recombined with the pLenti6.2-Dest/V5 lentiviral vector by LR recombination using the Gateway cloning technology (Invitrogen). The pLenti6.2-Dest/V5 empty vector control (referred to as vect) was generated by recombination of the destination lentiviral vector with a circularized empty pENTR-D/TOPO plasmid to replace the attR1-CmR-ccdB-attR2 toxic protein from the pLenti6.2-Dest/V5 vector.
The murine stem-cell retroviral (MSCV) vectors pMigR1-210 and pMigR1-185 carrying the Bcr-abl (p210 and p185) full-length fusion gene cDNAs were kindly provided by Dr Ann Marie Pendergast of Duke University. Both plasmid constructs are bicistronic with an internal ribosomal entry site (IRES) upstream of the enhanced green fluorescent protein (eGFP) coding sequence. To generate the matched empty vector control pMSCV-IRES-eGFP (pMiG), the 7.2-kb (kilobase) EcoRI fragment coding for p210 Bcr-abl fusion protein was released, and the vector was religated with T4 DNA ligase.
To construct the ␤-catenin/Tcf reporter gene system, the synthetic sense and antisense strands of the Tcf-binding sites 1 (TBS-1) and Tcf-binding sites 2 (TBS-2) were denatured at 94°C and annealed at room temperature. 11, 12 The ds-TBS-1/2 was 3Ј adenine-tailed with Taq DNA polymerase at 72°C for 15 minutes followed by in vitro phosphorylation of the 5Ј-OH ends with T4 polynucleotide kinase. The resultant double-stranded ds-TBS-1/2 was inserted into pGEM/Tesay vector (Promega, Madison, WI) by T/A cloning. The TBS-1/2 inserts flanked by XhoI and HindIII sites were excised from the T/A vector, and the released TBS-1/2 oligonucleotides were ligated into the XhoI-HindIII site of the multiple cloning site in phRL-null Renilla luciferase vector (Promega). To construct the Tcf optimal promoter (TOP)/minimal thymidine kinase (mTK) chimeric promoter upstream of the Renilla luciferase coding sequence, a 531-bp (base pair) BglII-PvuII cohesive-blunt fragment of the thymidine kinase promoter region was deleted from the phRL-TK vector (Promega) and replaced with the BglII-SmaI cohesive-blunt fragment containing the TBS-1/2 fragments released from the phRL-TBS-1/2. To construct the Bcr-abl promoter reporter, the pMigR1-210 was first digested with BamHI. The resulting BamHI 5Ј-overhangs were fill-in blunted with Klenow. A 640-bp EcoRI-BamHI fragment (pp210S) and an approximately 1.5-kb BamHI-EcoRI fragment (pp210L), spanning the putative Bcr-abl promoter region and part of the first exon, 13 was further released from the linearized pMigR1-210 and inserted directionally (for pp210S) and in reverse direction (for pp210L) into the EcoRI-SmaI site of the phRL-null Renilla luciferase vector. All the synthetic oligonucleotides for long and accurate-polymerase chain reaction amplification of relevant gene CDSs, or for construction of TOP-mTK chimeric promoters, are indicated in Table S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article). At the 5Ј-end of each forward primer, a CACC 5Ј-overhang was added to the primer to ensure directional ligation into pENTR-D/TOPO vector and to constitute the Kozak consensus sequence (CACCATGC/G) for efficient translational initiation. At the 3Ј-end of each reverse primer, the TGA/TAG stop codons were site-directionally mutated into AGA to allow downstream V5 epitope expression. For the Tcf binding sites 1 and 2, the XhoI and HindIII restriction sites are underlined, respectively.
Production of lentiviral and retroviral stocks
To generate replication-incompetent lentiviral particles carrying the CDH5-wt, ⌬bcat, ⌬cyto, and vect, the pLenti6.2-Dest/V5 vectors containing the gene CDSs described were cotransfected with pLP1 (gag/pol), pLP2 (rev), and pLP3 (VSV-G, vesicular stomatitis virus-G pseudotype) plasmids (Invitrogen) into 293FT packaging cells (Invitrogen). To generate the replication-incompetent murine stem cell retroviruses expressing the p210/ p185 Bcr-abl fusion protein, the pMigR1-210, pMigR1-185, or pMiG empty vector constructs were transfected into the RetroPack PT67 packing cells (BD-Clontech, San Jose, CA), in which the gag/pol, rev, and the pseudotyped VSV-G envelope coding sequences have been stably integrated into the PT67 genome. For detailed protocols of collection, titration, and cell infection, see the data supplement.
Dual-luciferase reporter (DLR) assay
To evaluate transactivation of the ␤-catenin/Tcf signaling and the Bcr-abl transcription activity initiated by long-term stromal cell coculture or enforced expression of VE-cadherin in Sup-B15 cells, cells were transiently cotransfected in triplicate with pGL4.13-CMV/Luc2 (Promega) firefly luciferase expression vector (as an internal transfection efficiency control) and the Renilla luciferase TOP1/2-mTK or Bcr-abl pp210S/pp210L promoter reporter constructs. For collection, cell lysis, and bioluminescence assay, see the data supplement.
Knockdown of VE-cadherin expression by RNAi
SmartPool short interfering RNAs (siRNAs) corresponding to coding sequences of VE-cadherin was obtained from Dharmacon (Lafayette, CO). Transient siRNA transfection of Sup-B15 cells was completed as previously described with the use of scrambled siRNA sequence controls.
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Endothelial differentiation
Evaluation of endothelial cell differentiation (ie, sprouting) of Sup-B15 and Nalm27 cells was completed as recommended by the manufacturer (Stem Cell Technologies, Toronto, Canada). Briefly, LTCC Ds-Red-labeled Sup-B15 or eGFP-labeled Nalm27 cells were collected and incubated in the EndoCult liquid medium supplemented with EndoCult supplements on cover slips. Forty-eight hours after induction of differentiation, cells were fixed in formaldehyde and analyzed by confocal microscopy.
Microarray analysis
Wnt, Notch, HSC, and cell surface marker pathway-focused microarray analyses of mRNA transcripts in Sup-B15 LTMCs/LTCCs were performed according to the manufacturer's instructions (SuperArray, Frederick, MD). For a brief protocol, see Document S1.
In vitro poly-ubiquitination of ␤-catenin
In vitro poly-ubiquitination was performed as described previously.
14 Briefly, ␤-catenin was immunoprecipitated either from 293FT cells expressing eGFP-210 or eGFP alone, or from Ph ϩ Sup-B15 or Ph Ϫ REH leukemic cells. The ubiquitin-protein conjugation reaction was performed at 37°C in a waterbath for 3.5 hours in a volume of 20 L containing 50 mM HEPES, pH 7.5, 2 mM DTT, 5 mM MgCl 2 , 5 mM ATP, Fraction A (including human E1 and E2 enzymes), Fraction B (containing human E3 enzyme), 10 g recombinant ubiquitin (BostonBiochem, Boston, MA) and immunoprecipitated ␤-catenin in the presence of 2 M ubiquitin C-terminal hydrolase inhibitor ubiquitin aldehyde. The BLOOD, 1 NOVEMBER 2007 ⅐ VOLUME 110, NUMBER 9 For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From reaction was terminated by the addition of 10 L 3ϫ SDS sample buffer and boiled at 100°C for 5 minutes.
Confocal microscopy, immunoprecipitation, immunoblotting, and flow cytometry
All confocal images were acquired on a Zeiss LSMS10 confocal system attached to an Axiovert 100M microscope. This system has 3 lasers (488, 543, and 633) and 3 PMTs to collect multiple fluorescent probes. The images were acquired and processed using the Zeiss LSMS10 software version 3.21 (Carl Zeiss, Thornwood, NY). All the antigen-antibody-based experiments were completed as described previously. 10, 15 Antibodies are described in detail in Document S1. All human-derived stromal cells were established from de-identified samples in compliance with the West Virginia University Institutional Review Board guidelines.
Results
Identification and characterization of a leukemic stem cell-like population that expresses both endothelial and hematopoietic progenitor cell surface markers
Both p185 (Sup-B15) and p210 (Nalm27 For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From to EDTA-free trypsin digestion during regular subculture, whereas leukemic cell aggregates in long-term medium culture (LTMC) can be disrupted by mechanic vibration.
Formation of flamelike, finger-shaped hematopoietic cords from Ph ϩ /VE-cadherin ϩ LTCC on both human and murine stromal cells follows formation and growth of hemospheres ( Figure 2B ; Video clips S1-S6). Hematopoietic cords were characterized by a bamboo shootlike structure composed of distinct cellular constituents localized to the peripheral or central regions ( Figure 2B ). In a typical hematopoietic cord, the inner column is composed of CD133 ϩ VE-cadherin ϩ cells with the periphery of the cord constituted by more differentiated CD133-VE-cadherin ϩ leukemic cells ( Figure 2B ; Video clips S3-S4). To further examine the stem cell potential of the leukemic cells that comprised the hemospheres and hematopoietic cords, we stained the hemosphere and hematopoietic cord cells with early stem cell (ESC) markers ( Figure 2C,D) . Confocal microscopy revealed distinct expression and distribution patterns of ESC markers. Oct-4 was uniquely expressed in the peripheral region of the hemospheres ( Figure 2D ), whereas SSEA-1-, SSEA-3-, SSEA-4-, Tra-1-61-, and Tra-1-80-positive cells were limited to the central region ( Figure 2C ). Migratory leukemic cells surrounding the hemospheres were negative for ESC marker staining (Figure 2C,D) . When LTCC Ph ϩ /VE-cadherin ϩ cells were incubated in EndoCult, we observed endothelial sprouting of Ph ϩ VE-cadherin ϩ Sup-B15 or Nalm 27 cells ( Figure 2E ). Many Ph ϩ VE-cadherin ϩ LTCC cells differentiated from round, floating cells to spindle-shaped, adherent cells within 2 days ( Figure 2E ). Thus, deprivation of stromal cell support in the presence of endothelial-trophic growth factors leads to a rapid endothelial switch of Ph ϩ /VE-cadherin ϩ cells after long-term stromal cell contact. Table S2 ). Tcf/␤-catenin target genes, including cyclin D1 (CCND1), cyclin D3 (CCND3), and c-Myc (MYC), were increased by 2-to 2.5-fold, 2-to 2.5-fold, and 3-to 3.5-fold, respectively, after LTCC. The ␤-catenin transcriptional coactivator Bcl-9 (BCL9) was upregulated 1.5-to 2-fold, whereas its transcriptional corepressor Tcf (TCF7) and the Wnt inhibitory factor 1 (WIF1) were down-regulated 2-and 1.5-fold, respectively. However, expression of the intracellular signaling mediator ␤-catenin (CTNNB1) and ␤-catenin binding protein 1 (CTNNB1P1) remained unchanged. Further, the leukemic cell autocrine Wnts, including Wnt1, Wnt2, and Wnt3A, were down-regulated by 2-to 2.3-fold in LTCC Sup-B15 compared with those of LTMC Sup-B15, which were coincident with down-regulation of the Wnt coreceptor Frizzled (FZD3; 1.5-fold) and the secretory Wnt precursorprocessing protein (PORCN; 2-fold). Thus, Wnt signaling cascades downstream of ligand/receptor occupancy were aberrantly intercepted and reinforced, whereas the extracellular component of the signaling pathway was attenuated or disabled in Ph ϩ /VE-cadherin ϩ ALL cells during LTCC.
Stromal cells up-regulate VE-cadherin expression and stabilize
The convergence of ␤-catenin in cadherin-catenin-mediated cellcell adhesion and morphogenesis, and as an intracellular mediator of the canonical Wnt signaling pathway, prompted us to hypothesize that VE-cadherin expression may contribute to self-renewal and proliferation of Ph ϩ /VE-cadherin ϩ cells. After LTCC of Sup-B15 with both murine and human marrow stromal cells, VE-cadherin expression was up-regulated, coincident with elevated Src expression and ␤-catenin accumulation ( Figure 4A) . Screening a panel of stromal cell-soluble growth factors and cytokines showed that TGF-␤1, bFGF, and VEGF stimulated VE-cadherin expression on Sup-B15 cells by 2.0-, 1.50-, and 1.8-fold, respectively ( Figure 4B ). To determine whether upregulated VE-cadherin contributes to stabilizing ␤-catenin in Ph ϩ /VE-cadherin ϩ ALL cells, reciprocal coimmunoprecipitation revealed that the amount of ␤-catenin complexed with VE-cadherin in tumor cells derived from either S10 or PatX LTCC were 2-to 3.5-fold higher than those from LTMC alone ( Figure 4C ). Because microarray data indicated that ␤-catenin expression is not influenced by stromal cell contact (Figure 3) , we hypothesized that up-regulated VE-cadherin plays a major role in sequestering and stabilizing ␤-catenin in Ph ϩ /VE-cadherin ϩ cells. To investigate this possibility, lentiviral transduction of Sup-B15 and 293FT cells with vectors carrying the wild-type and 2 mutant forms of VE-cadherin, ⌬bcat, and ⌬cyto, were established ( Figure 4D) . Expression of the wt VE-cadherin, but not VE-cadherin lacking either the cytoplasmic or ␤-catenin binding domains, led to approximately 4-fold more ␤-catenin accumulation in both 293FT ( Figure 4D 
␤-Catenin is constitutively activated in leukemic stem-like cells that overexpress VE-cadherin during LTCC
To examine the ␤-catenin/Tcf transcriptional activity, Sup-B15 LTMC or LTCC cells were transiently cotransfected with phRL-TOP1 or phRL-TOP2 (Renilla luciferase) with an internal control plasmid, pGL4.13-CMV-Luc2 (firefly luciferase). Stromal cell contact resulted in a 5-to 13-fold increase in relative luciferase activity in LTCC ( Figure 5A ). Moreover, enforced expression of the wt, but not ⌬bcat and ⌬cyto, VE-cadherin significantly promoted ␤-catenin/Tcf transcriptional activity in Sup-B15 cells ( Figure 5B ). In contrast, depletion of VEcadherin expression by siRNA resulted in an unexpected, transient elevation of ␤-catenin activity during the first 8 hours BLOOD, 1 NOVEMBER 2007 ⅐ VOLUME 110, NUMBER 9 For personal use only. on April 13, 2017. by guest www.bloodjournal.org From after transfection, followed by a persistent declining in relative luciferase activities in a time-dependent ( Figure 5C top) and siRNA concentration-dependent ( Figure 5C bottom) manner. One interpretation of this interesting phenomenon is that the initial reduction of the docking protein VE-cadherin releases ␤-catenin capable of driving luciferase reporter expression because of the release of excessive, free ␤-catenin that cannot be efficiently targeted for proteosome-mediated degradation. However, long-term reduction of VE-cadherin may diminish its capability to protect ␤-catenin from targeted ubiquitination and degradation that is typically achieved through physical interaction. Stromal cell signals also altered the intracellular distribution of ␤-catenin in Ph ϩ /VE-cadherin ϩ cells. Translocation of ␤-catenin from the cytoplasm to the nucleus in Sup-B15 cells was sporadically observed in actively dividing cells in LTMC ( Figure 5D) ; however, long-term coculture of Sup-B15 cells consistently promoted nuclear translocation of ␤-catenin in most of the leukemic cells on hematopoietic cords ( Figure 5D ).
Bcr-abl fusion protein is essential for maintaining the VE-cadherin/␤-catenin axis in the leukemic stemlike cells
In 293FT cells transduced with various forms of VE-cadherinexpressing lentiviral vectors, forced wild-type VE-cadherin stabilized ␤-catenin compared with vector control, ⌬bcat, or ⌬cyto VE-cadherin ( Figure 4D top) . However, the ␤-catenin/Tcf transcriptional activity did not dramatically change after transduction of vect, ⌬bcat, ⌬cyto, or even wt VE-cadherin in 293FT cells (data not shown). Therefore, VE-cadherin expression alone is probably necessary, but not sufficient, to maintain enhanced ␤-catenin activity in VE-cadherin ϩ leukemic cells. We hypothesized that the Bcr-abl fusion protein, with constitutive tyrosine kinase activity, may synergize with VE-cadherin expression to contribute to the unique phenomenon of leukemic cell selfrenewal and proliferation. To test this, we examined the alteration of Bcr-abl protein expression in LTMC and LTCC leukemic cells and observed that stromal cell contact upregulated both Abl and Bcr-abl protein expression by 1.5-to 2-fold ( Figure 6A top) . To confirm the observation at the transcriptional level, the Bcr-abl fusion gene promoter region was cloned into the phRL-null luciferase reporter vector. The relative luciferase activity was up-regulated 2-to 4-fold in Sup-B15 LTCC with S10 or PatX as assayed by the pp210S, but not the pp210L, reporter ( Figure 6A bottom) . To further investigate the role of the Bcr-abl fusion protein, Sup-B15 cells were infected with retroviruses carrying either the p185 or p210 Bcr-abl full-length cDNA. Retroviral transduction of both p185 and p210 Bcr-abl resulted in forced expression of p185 or p210 protein in Sup-B15 cells (Figure 6B top) . In Sup-B15 cells overexpressing the p185-eGFP or p210-eGFP proteins, upregulation of VE-cadherin was also detected as above the parental baseline ( Figure 6B bottom) . Consistent with upregulated VE-cadherin expression, ␤-catenin/Tcf activity was also increased 7-to 14-fold in p185-eGFP-and p210-eGFPexpressing cells compared with eGFP expression alone ( Figure  6C ). In contrast, inhibition of Bcr-abl activity with the tyrosine kinase inhibitors IM or AG957 down-regulated VE-cadherin expression in a concentration-dependent fashion in Sup-B15 cells, coincident with ␤-catenin cleavage ( Figure 6D ). In contrast, treatment of Ph ϩ /VE-cadherin ϩ leukemic cells with the proteosome inhibitor MG132 diminished imatinib mesylateinduced cleavage of ␤-catenin in both Sup-B15 and Nalm27 cells ( Figure 6E ).
Tyrosine phosphorylation of ␤-catenin mediated by Bcr-abl kinase diminishes its ubiquitination-proteosome-dependent degradation
To dissect the signaling pathway by which constitutive Bcr-abl kinase activity maintains higher VE-cadherin/␤-catenin in Ph ϩ /VEcadherin ϩ ALL cells, Ph Ϫ /VE-cadherin Ϫ 293FT cells were cotransduced with lentiviruses encoding VE-cadherin and retroviruses encoding the p210 Bcr-abl fusion protein. VE-cadherin/p210 dual transduction resulted in the most pronounced stabilization of ␤-catenin in 293FT cells compared with VE-cadherin transduction alone ( Figure 7A ). Immunoprecipitation of ␤-catenin from the same samples indicated that ␤-catenin and Src coexisted in the same immunocomplexes and that ␤-catenin was tyrosine-phosphorylated after transduction with p210 Bcr-abl kinase ( Figure 7B ). This was consistent with the most pronounced ␤-catenin transcriptional activity being detected in p210 and VE-cadherin cotransduced cells ( Figure 7C ). Inhibition of Src activity with PP2, or Bcr-abl with imatinib mesylate, was correlated with modest reduction of ␤-catenin recognized by a monoclonal antibody specific for its active form. The combinatory inhibition of Src and Bcr-abl kinase activity was associated with a further reduction in ␤-catenin ( Figure 7D ). VE-cadherin was immunoprecipitated from the same panel. Although expression of Bcr-abl protein resulted in a number of tyrosine-phosphorylated proteins, VE-cadherin appeared not to be affected by this constitutively active kinase ( Figure  7E ). To investigate whether tyrosine-phosphorylated ␤-catenin is more stable or resistant to the ubiquitin-proteosome-mediated protein degradation pathway, ␤-catenin that was immunoprecipitated from Ph ϩ/Ϫ leukemia or 293FT cells expressing eGFP-p210/ eGFP was subjected to an in vitro ubiquitination and degradation assay. In the presence of endogenous (Ph ϩ ) or exogenously expressed Bcr-abl (eGFP-Bcr-abl), ␤-catenin had less mono-, poly-ubiquitination, and degraded fractions. This effect was shown by comparison of Ph ϩ Sup-B15 or 293FT/eGFP-p210 to Ph Ϫ REH or 293FT/eGFP cells ( Figure 7F) . Thus, consistent with the recent reports that Bcr-abl fusion protein promotes Src activation and that Bcr-abl mediates tyrosine BLOOD, 1 NOVEMBER 2007 ⅐ VOLUME 110, NUMBER 9
For personal use only. on April 13, 2017 . by guest www.bloodjournal.org From phosphorylation and subsequent stabilization of ␤-catenin in Ph ϩ ALL cells, 20, 21 our data indicated that up-regulated Bcr-abl fusion protein contributes to constitutively active ␤-catenin activity by promoting VE-cadherin expression (physical stabilization) and subsequently converting VE-cadherin-stabilized ␤-catenin to the active form through Src-mediated tyrosine phosphorylation (functional stabilization). These data also suggest that tyrosine phosphorylation and serine/threonine phosphorylation may differentially influence the fate of ␤-catenin by affecting its subsequent ubiquitination.
Discussion
Compared with the LSC model of AML, the origin of ALL LSCs is less well characterized. Studies indicated that primitive HSCs were the target for ALL LSC transformation. [22] [23] [24] In contrast,
Castor et al 25 showed that different genetic alterations may target different stages of hematopoiesis in ALL. The p210 Bcr-abl targeted primitive HSCs, whereas p185 and TEL-AML1 can transform CD34 ϩ CD19 ϩ B-cell progenitors, 25 raising the question whether LSCs for Ph ϩ ALL may also derive from committed B-cell progenitors. Our data support the hypothesis that LSCs of B-cell Ph ϩ ALL can originate from committed progenitor cells. In the current study, we identified a CD34 ϩ CD38 ϩ CD19 ϩ Ph ϩ/Ϫ ALL subpopulation with leukemic stem cell-like properties (Figures 1,2) . Formation of hematopoietic colonies (hemospheres) and cords, induction of endothelial sprouting, and reactivation of early stem cell genes in this CD34 ϩ CD38 ϩ CD19 ϩ subset during LTCC are consistent with a leukemic stem cell phenotype (Figure 2 unique setting ( Figure 6 ). In agreement with this possibility, a report showed that Bcr-abl fusion transcripts can be detected in endothelial cells derived from transplanted bone marrow cells from a patient with CML. 26 This in vivo observation, together with our in vitro induction of endothelial differentiation of Ph ϩ /VE-cadherin ϩ ALL cells (Figure 2 ), supports the conclusion that Bcr-abl alone may promote VE-cadherin expression ( Figure 6 ) and contribute to vascular endothelium potential. 26 Intriguingly, normal myeloid progenitors can also differentiate into endothelial cells, 27 further supporting the notion that determination of endothelial fate is not restricted to the hemangioblast or HSC stage, but rather reflects the close developmental relation between the hematopoietic and vascular systems. VE-cadherin expression in nonendothelial cells has been identified and characterized in 2 additional cell types to date. Increased VE-cadherin expression on cytotrophoblast stem cells was required for normal placentation and successful endovascular invasion. 28 In addition, VE-cadherin was expressed in highly aggressive melanoma and contributed to vascular mimicry. 29 Notable are the observations that gestational trophoblastic neoplasia and aggressive melanoma are highly metastatic with frequent central nervous system involvement. 30, 31 It is also widely recognized that, compared with acute nonlymphoblastic leukemia, non-Hodgkin lymphoma, or Hodgkin lymphoma, ALL is clinically manifested with a much higher frequency of central nervous system (CNS) involvement. Because nonendothelial cells with VE-cadherin expression identified so far share a common clinical feature, CNS involvement, it is tempting to speculate that VE-cadherin expression plays an important role in mediating invasion of Ph ϩ /VE-cadherin ϩ ALL cells into the CNS. Identification of the importance of the Bcr-abl/VE-cadherin/␤-catenin axis and lack of reliance on Wnt initiated signals indicate that this subset of tumor cells can circumvent the requirement of exogenous Wnts for sustained self-renewal activity (Figures 4,5) . This self-renewal autonomy is sustained by stabilized ␤-catenin in the presence of VE-cadherin expression ( Figure 4 ) coincident with high Bcr-Abl kinase activity. Thus, these Ph ϩ /VE-cadherin ϩ cells can bypass the de novo signaling cascade initialized by Wnt ligands for self-renewal and proliferation. Therefore, our data characterize a novel model in which the molecular basis underlying the self-renewal autonomy of Ph ϩ ALL LSCs can be further investigated.
Although Wnt/␤-catenin-mediated self-renewal is similar in many tumor models, the epigenetic and genetic alterations imposed on the tumor by the microenvironment are diverse. Self-renewal autonomy conferred by intrinsically active ␤-catenin reflects one of the differences between normal hematopoietic stem cells and leukemic stem cells, because normal stem cells exquisitely rely on self-renewal signals from supportive niches, 32 whereas cancer stem cells can somewhat escape this dependency. However, a lack of reliance by tumor cells on niche-derived signals does not indicate a loss of ability to respond to these important microenvironmental cues. In our model, bone marrow stromal cells modulate the ␤-catenin-mediated self-renewal capacity by up-regulating VEcadherin and Bcr-abl expression (Figures 4,6 ). This observation is consistent with a report that up-regulation of Bcr-abl transcripts, followed by nuclear translocation of ␤-catenin, plays an important role during LSC transformation to CML blast crisis. 33 Coexpression of VE-cadherin and Bcr-abl is unique to the subset of putative LSCs used in this model, with our data suggesting that microenvironmental factors remain influential in augmenting the self-renewal potential of specific LSCs.
In addition, recent studies indicated that conditional expression of constitutively active ␤-catenin in knock-in mice led to the exhaustion of the long-term hematopoietic stem cell pool and loss of stem cell-repopulating activity. 34, 35 This raised the question whether constitutively active ␤-catenin also impairs the plasticity of leukemic stem cells. Although ␤-catenin is constitutively active in LTCC Ph ϩ VE-cadherin ϩ cells, in the presence of stromal cells, many early stem cell genes were reactivated in Ph ϩ ALL leukemic cells physically located in hemospheres (Figure 2 ). These early stem cell markers were previously shown to be expressed in primitive embryonic stem cells and serve as indicators of quiescence and pluripotency of embryonic stem cells. 36 The observation that tumor cells expressed early stem cell markers in a specific anatomical configuration, with hemosphere structure initiation supported by physical attachment to bone marrow stromal cells, was striking. This observation suggests that stromal cell dependency distinguishes primitive leukemic stem cells from more differentiated progeny leukemic cells. Further, our data also suggest that leukemic cells in long-term coculture with stroma are highly heterogeneous, and in vitro LTCC may partially mimic the hierarchical differentiation of the hematopoietic stem/progenitor cells in the bone marrow microenvironment. The concept of "reprogramming" differentiated cells to a stem cell-like phenotype has been addressed by several groups, including a recent report that the combination of 4 transcriptional factors, Oct-3/4, Sox2, c-myc, and klf4, can reprogram terminally differentiated mouse fibroblasts into pluripotent embryonic stem cells. 37 Our data suggest that Ph ϩ /VE-cadherin ϩ ALL cell gene expression profiles may be uniquely modified by stromal cells and support the hypothesis that formation of hemospheres with distinct stem cell marker expression may reflect an attempt by bone marrow stromal cells to balance the proliferating pool with the primitive, quiescent pool of LSCs. Therefore, unlike their normal hematopoietic counterparts, 34, 35 the LSC subpopulation of Ph ϩ VE-cadherin ϩ ALL cells may not be exhausted even if constitutively active ␤-catenin is driving cell-cycle entry, because of stromal cell conversion of a pool of LSCs to a quiescent state. Thus, self-renewal autonomy and stromal cell dependence of Ph ϩ VE-cadherin ϩ ALL cells may be integrated in a way that positions them to contribute to the relapse of disease through characteristics they share with normal HSCs.
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